The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates

Urologic Clinics of North America

Volumn 43, Issue 3, 2016, Pages 289-297

  Egan, Kathryn Brigham ^a,b  

^a YALE UNIVERSITY   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

Aging; Benign prostatic hyperplasia; Incidence; Lower urinary tract symptoms; Prevalence; Prostate disease; Urology

Indexed keywords

AGE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ETHNICITY; HUMAN; LOWER URINARY TRACT SYMPTOM; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RACE; REVIEW; RISK FACTOR; COMPLICATION; GLOBAL HEALTH; INCIDENCE; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE;

GLOBAL HEALTH; HUMANS; INCIDENCE; LOWER URINARY TRACT SYMPTOMS; MALE; PREVALENCE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE;

EID: 84991666271     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2016.04.001     Document Type: Review

References (52)

1. 1 Roehrborn, C.G., Benign prostatic hyperplasia: an overview. Rev Urol 7:Suppl 9 (2005), S3–s14.
2. 2 Abrams, P., Cardozo, L., Fall, M., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61 (2003), 37–49.
3. 3 Maserejian, N.N., Chen, S., Chiu, G.R., et al. Incidence of lower urinary tract symptoms in a population-based study of men and women. Urology 82 (2013), 560–564.
4. 4 Litman, H.J., McKinlay, J.B., The future magnitude of urological symptoms in the USA: projections using the Boston Area Community Health survey. BJU Int 100 (2007), 820–825.
5. 5 Auffenberg, G.B., Helfand, B.T., McVary, K.T., Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 36 (2009), 443–459 v-vi.
6. 6 Anderson, J.B., Roehrborn, C.G., Schalken, J.A., et al. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 39 (2001), 390–399.
7. 7 McNeal, J., Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 17 (1990), 477–486.
8. 8 Park, H.J., Won, J.E., Sorsaburu, S., et al. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on Tadalafil. World J Mens Health 31 (2013), 193–207.
9. 9 Rhodes, P.R., Krogh, R.H., Bruskewitz, R.C., Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 53 (1999), 1090–1098.
10. 10 Barry, M.J., Fowler, F.J. Jr., O'Leary, M.P., et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care 33 (1995), As145–AS155.
11. 11 Barry, M.J., Fowler, F.J. Jr., O'Leary, M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148 (1992), 1549–1557 [discussion: 1564].
12. 12 Egan, K.B., Burnett, A.L., McVary, K.T., et al. The co-occurring syndrome-coexisting erectile dysfunction and benign prostatic hyperplasia and their clinical correlates in aging men: results from the national health and nutrition examination survey. Urology 86 (2015), 570–580.
13. 13 Roehrborn, C.G., Nuckolls, J.G., Wei, J.T., et al. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int 100 (2007), 813–819.
14. 14 Kirby, M., Chapple, C., Jackson, G., et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract 67 (2013), 606–618.
15. 15 Kristal, A.R., Arnold, K.B., Schenk, J.M., et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 177 (2007), 1395–1400 [quiz: 1591].
16. 16 Parsons, J.K., Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. Curr Opin Urol 21 (2011), 1–4.
17. 17 Wei, J.T., Calhoun, E., Jacobsen, S.J., Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173 (2005), 1256–1261.
18. 18 Blanker, M.H., Bohnen, A.M., Groeneveld, F.P., et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 49 (2001), 436–442.
19. 19 Coyne, K.S., Kaplan, S.A., Chapple, C.R., et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int 103:Suppl 3 (2009), 24–32.
20. 20 Bosch, J.L., Hop, W.C., Kirkels, W.J., et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 46 (1995), 34–40.
21. 21 Lee, A.J., Garraway, W.M., Simpson, R.J., et al. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 34 (1998), 325–332.
22. 22 Berry, S.J., Coffey, D.S., Walsh, P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984), 474–479.
23. 23 Garraway, W.M., Collins, G.N., Lee, R.J., High prevalence of benign prostatic hypertrophy in the community. Lancet 338 (1991), 469–471.
24. 24 Meigs, J.B., Mohr, B., Barry, M.J., et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54 (2001), 935–944.
25. 25 Sarma, A.V., Jacobson, D.J., McGree, M.E., et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 173 (2005), 2048–2053.
26. 26 Kupelian, V., Wei, J.T., O'Leary, M.P., et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 166 (2006), 2381–2387.
27. 27 Da Silva, F.C., Benign prostatic hyperplasia: natural evolution versus medical treatment. Eur Urol 32:Suppl 2 (1997), 34–37.
28. 28 Napalkov, P., Maisonneuve, P., Boyle, P., Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 46 (1995), 41–46.
29. 29 De Marzo, A.M., Marchi, V.L., Epstein, J.I., et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155 (1999), 1985–1992.
30. 30 Girman, C.J., Jacobsen, S.J., Guess, H.A., et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 153 (1995), 1510–1515.
31. 31 Chute, C.G., Panser, L.A., Girman, C.J., et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150 (1993), 85–89.
32. 32 McVary, K.T., BPH: epidemiology and comorbidities. Am J Manag Care 12 (2006), S122–S128.
33. 33 Bosch, J.L., Hop, W.C., Kirkels, W.J., et al. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 75 (1995), 622–630.
34. 34 Sagnier, P.P., MacFarlane, G., Richard, F., et al. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 151 (1994), 1266–1270.
35. 35 Chicharro-Molero, J.A., Burgos-Rodriguez, R., Sanchez-Cruz, J.J., et al. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol 159 (1998), 878–882.
36. 36 Rhodes, T., Girman, C.J., Jacobsen, S.J., et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161 (1999), 1174–1179.
37. 37 Bushman, W., Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36 (2009), 403–415 v.
38. 38 Vesely, S., Knutson, T., Damber, J.E., et al. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol 37 (2003), 322–328.
39. 39 Ezz el Din, K., Kiemeney, L.A., de Wildt, M.J., et al. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 48 (1996), 393–397.
40. 40 Van Den Eeden, S.K., Shan, J., Jacobsen, S.J., et al. Evaluating racial/ethnic disparities in lower urinary tract symptoms in men. J Urol 187 (2012), 185–189.
41. 41 Wei, J.T., Schottenfeld, D., Cooper, K., et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 165 (2001), 1521–1525.
42. 42 Jin, B., Turner, L., Zhou, Z., et al. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab 84 (1999), 3613–3619.
43. 43 Masumori, N., Tsukamoto, T., Kumamoto, Y., et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol 155 (1996), 1324–1327.
44. 44 Platz, E.A., Smit, E., Curhan, G.C., et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology 59 (2002), 877–883.
45. 45 Verhamme, K.M., Dieleman, J.P., Bleumink, G.S., et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42 (2002), 323–328.
46. 46 Platz, E.A., Joshu, C.E., Mondul, A.M., et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 188 (2012), 496–501.
47. 47 Clifford, G.M., Logie, J., Farmer, R.D., How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol 38:Suppl 1 (2000), 48–53.
48. 48 Logie, J.W., Clifford, G.M., Farmer, R.D., et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction–Triumph: the role of general practice databases. Eur Urol 39:Suppl 3 (2001), 42–47.
49. 49 Tsukamoto, T., Kumamoto, Y., Masumori, N., et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 154 (1995), 391–395.
50. 50 Guess, H.A., Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 14 (1992), 131–153.
51. 51 Nickel, J.C., Benign prostatic hyperplasia: does prostate size matter?. Rev Urol 5:Suppl 4 (2003), S12–S17.
52. 52 Platz, E.A., Kawachi, I., Rimm, E.B., et al. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study. J Urol 163 (2000), 490–495.